Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors (TKIs) in patients (pts) with Philadelphia chromosome–positive (Ph+) leukemia: Phase 1/2 study update.

Carlo Gambacorti‐Passerini,Jeffrey H. Lipton,Andreas Hochhaus,Vamsi Kota,Michele Baccarani,Simon Durrant,Sarit Assouline,Dong-Wook Kim,Tim H. Brümmendorf,Eric Leip,Fiona An,Jean M. Aguiar,Jorge E. Cortés

Journal of Clinical Oncology（2018）

引用 5|浏览2

暂无评分

摘要

7062Background: Bosutinib has a distinct adverse event (AE) profile vs other TKIs used to treat Ph+ leukemia. Methods: Pts with chronic phase (CP) chronic myeloid leukemia (CML; n=403) or accelerat...

查看译文

关键词

prior tyrosine kinase inhibitors,leukemia,bosutinib,tkis,cross-intolerance

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要